FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4368374280> ?p ?o ?g. }

• W4368374280 endingPage "10" @default.
• W4368374280 startingPage "3" @default.
• W4368374280 abstract "Background To evaluate the clinical features, demographic features, and treatment modalities of pediatric-onset chronic inflammatory demyelinating polyneuropathy (CIDP) in Turkey. Methods The clinical data of patients between January 2010 and December 2021 were reviewed retrospectively. The patients were evaluated according to the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society Guideline on the management of CIDP (2021). In addition, patients with typical CIDP were divided into two groups according to the first-line treatment modalities (group 1: IVIg only, group 2: IVIg + steroid). The patients were further divided into two separate groups based on their magnetic resonance imaging (MRI) characteristics. Results A total of 43 patients, 22 (51.2%) males and 21 (48.8%) females, were included in the study. There was a significant difference between pretreatment and post-treatment modified Rankin scale (mRS) scores (P < 0.05) of all patients. First-line treatments include intravenous immunoglobulin (IVIg) (n = 19, 44.2%), IVIg + steroids (n = 20, 46.5%), steroids (n = 1, 2.3%), IVIg + steroids + plasmapheresis (n = 1, 2.3%), and IVIg + plasmapheresis (n = 1, 2.3%). Alternative agent therapy consisted of azathioprine (n = 5), rituximab (n = 1), and azathioprine + mycophenolate mofetil + methotrexate (n = 1). There was no difference between the pretreatment and post-treatment mRS scores of groups 1 and 2 (P > 0.05); however, a significant decrease was found in the mRS scores of both groups with treatment (P < 0.05). The patients with abnormal MRI had significantly higher pretreatment mRS scores compared with the group with normal MRI (P < 0.05). Conclusions This multicenter study demonstrated that first-line immunotherapy modalities (IVIg vs IVIg + steroids) had equal efficacy for the treatment of patients with CIDP. We also determined that MRI features might be associated with profound clinical features, but did not affect treatment response." @default.
• W4368374280 created "2023-05-05" @default.
• W4368374280 creator A5001917710 @default.
• W4368374280 creator A5003327237 @default.
• W4368374280 creator A5007179260 @default.
• W4368374280 creator A5009069329 @default.
• W4368374280 creator A5011997133 @default.
• W4368374280 creator A5012350963 @default.
• W4368374280 creator A5016320571 @default.
• W4368374280 creator A5016449904 @default.
• W4368374280 creator A5016948271 @default.
• W4368374280 creator A5025289031 @default.
• W4368374280 creator A5025309094 @default.
• W4368374280 creator A5030728205 @default.
• W4368374280 creator A5032445959 @default.
• W4368374280 creator A5032823148 @default.
• W4368374280 creator A5033446291 @default.
• W4368374280 creator A5037756714 @default.
• W4368374280 creator A5040390277 @default.
• W4368374280 creator A5041739255 @default.
• W4368374280 creator A5050077220 @default.
• W4368374280 creator A5053169642 @default.
• W4368374280 creator A5053903018 @default.
• W4368374280 creator A5055902226 @default.
• W4368374280 creator A5059301820 @default.
• W4368374280 creator A5062344955 @default.
• W4368374280 creator A5066559062 @default.
• W4368374280 creator A5071455624 @default.
• W4368374280 creator A5073434588 @default.
• W4368374280 creator A5075734505 @default.
• W4368374280 creator A5077366174 @default.
• W4368374280 creator A5080894272 @default.
• W4368374280 creator A5083311102 @default.
• W4368374280 creator A5084675601 @default.
• W4368374280 creator A5085477097 @default.
• W4368374280 creator A5086191348 @default.
• W4368374280 creator A5087914226 @default.
• W4368374280 creator A5026790261 @default.
• W4368374280 date "2023-08-01" @default.
• W4368374280 modified "2023-10-18" @default.
• W4368374280 title "Pediatric-Onset Chronic Inflammatory Demyelinating Polyneuropathy: A Multicenter Study" @default.
• W4368374280 cites W1971491308 @default.
• W4368374280 cites W1979583574 @default.
• W4368374280 cites W1980310072 @default.
• W4368374280 cites W1986800768 @default.
• W4368374280 cites W1986962908 @default.
• W4368374280 cites W2004245477 @default.
• W4368374280 cites W2037633735 @default.
• W4368374280 cites W2037739554 @default.
• W4368374280 cites W2051652336 @default.
• W4368374280 cites W2056747399 @default.
• W4368374280 cites W2059843359 @default.
• W4368374280 cites W2060831235 @default.
• W4368374280 cites W2065030744 @default.
• W4368374280 cites W2071901778 @default.
• W4368374280 cites W2086753880 @default.
• W4368374280 cites W2092285771 @default.
• W4368374280 cites W2092928842 @default.
• W4368374280 cites W2110349010 @default.
• W4368374280 cites W2122361015 @default.
• W4368374280 cites W2122551863 @default.
• W4368374280 cites W2128687920 @default.
• W4368374280 cites W2172461869 @default.
• W4368374280 cites W2273588623 @default.
• W4368374280 cites W2395263494 @default.
• W4368374280 cites W2522365010 @default.
• W4368374280 cites W2768307074 @default.
• W4368374280 cites W2793879130 @default.
• W4368374280 cites W2802707556 @default.
• W4368374280 cites W2808024167 @default.
• W4368374280 cites W2897774458 @default.
• W4368374280 cites W2944167382 @default.
• W4368374280 cites W2966992451 @default.
• W4368374280 cites W3010344840 @default.
• W4368374280 cites W302093493 @default.
• W4368374280 cites W3025563471 @default.
• W4368374280 cites W3029729293 @default.
• W4368374280 cites W3084227145 @default.
• W4368374280 cites W3096614765 @default.
• W4368374280 cites W3121346121 @default.
• W4368374280 cites W3132071973 @default.
• W4368374280 cites W3164824044 @default.
• W4368374280 cites W3184985178 @default.
• W4368374280 doi "https://doi.org/10.1016/j.pediatrneurol.2023.04.018" @default.
• W4368374280 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37245275" @default.
• W4368374280 hasPublicationYear "2023" @default.
• W4368374280 type Work @default.
• W4368374280 citedByCount "0" @default.
• W4368374280 crossrefType "journal-article" @default.
• W4368374280 hasAuthorship W4368374280A5001917710 @default.
• W4368374280 hasAuthorship W4368374280A5003327237 @default.
• W4368374280 hasAuthorship W4368374280A5007179260 @default.
• W4368374280 hasAuthorship W4368374280A5009069329 @default.
• W4368374280 hasAuthorship W4368374280A5011997133 @default.
• W4368374280 hasAuthorship W4368374280A5012350963 @default.
• W4368374280 hasAuthorship W4368374280A5016320571 @default.
• W4368374280 hasAuthorship W4368374280A5016449904 @default.
• W4368374280 hasAuthorship W4368374280A5016948271 @default.

• next